Viral load is the quantity of virus in a given amount of patient’s blood.
Synonyms
Virus load
Detailed description
This factor is mainly used to control the therapeutic process of infections with HIV, cytomegaly viruses, hepatitis A viruses and hepatitis B viruses. A high viral load correlates with a severe infection or a poor prognosis, respectively.
Initial associations with the term “emerging infections” usually involve diseases like Ebola and MERS or chikungunya and Zika fever. However, dangerous zoonoses, i.e. viral infections that can spread
The Usutu virus endangers birds and has been circulating in Germany since 2010. However, estimating its impact on bird populations in the outbreak region has hardly been possible up to now. For the
Scientists have elucidated the Zika burden in a Brazilian metropolis. Their data indicate: the outbreak may be coming to an end and further outbreaks in the region seem unlikely. The study has also
A research team from Marburg, Heidelberg and Kyoto elucidates the structure and assembly of the Ebola virus’ genome envelope. This envelope protects the epidemic pathogen’s genome from being broken
An international team of researchers has successfully tested a vaccine against the Ebola virus: The medical experts have established a dose which could offer successful protection against the Ebola
For over 20 years, Professor Andreas Peschel from the Interfaculty Institute of Microbiology and Infection Medicine Tübingen (IMIT) and the German Center for Infection Research (DZIF) has dedicated
The latest outbreaks of emerging, dangerous pathogens, such as Ebola, MERS-CoV or Zika, emphasise the importance of the rapid development of effective vaccines. However, being able to predict the
Some HIV-infected – and untreated children – who do not develop AIDS, control the virus in a different way from the few infected adults who remain disease-free. Dr Maximilian Muenchhoff, DZIF
Prof Marcus Altfeld and Dr Angelique Hölzemer from the Heinrich Pette Institute (HPI) have been honoured with the "Hector Award HIV 2017”. Both scientists also work at the DZIF research field HIV.
The European Medicines Agency (EMA) has granted “PRIME eligibility” to Myrcludex B, and will provide priority support for its further drug development. The hepatitis B and D virus entry inhibitor was
